Resona Asset Management Co. Ltd. Raises Position in CVS Health Corporation $CVS

Resona Asset Management Co. Ltd. lifted its stake in shares of CVS Health Corporation (NYSE:CVS) by 1.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 415,595 shares of the pharmacy operator’s stock after acquiring an additional 6,396 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in CVS Health were worth $29,727,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of CVS. Caitong International Asset Management Co. Ltd increased its holdings in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. purchased a new position in shares of CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new position in shares of CVS Health during the fourth quarter worth about $28,000. Global Trust Asset Management LLC increased its stake in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the 4th quarter valued at $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Down 1.7%

Shares of NYSE:CVS opened at $102.69 on Friday. The stock has a market cap of $131.03 billion, a P/E ratio of 45.24, a P/E/G ratio of 1.02 and a beta of 0.61. The firm has a fifty day moving average price of $96.50 and a 200 day moving average price of $84.03. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $106.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the business posted $2.25 earnings per share. CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

Analyst Ratings Changes

CVS has been the topic of several recent analyst reports. Wall Street Zen raised CVS Health from a “hold” rating to a “buy” rating in a report on Tuesday. Robert W. Baird lifted their price target on CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Wells Fargo & Company raised their target price on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, DA Davidson boosted their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.84.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS drew bullish attention after Jim Cramer highlighted health insurance/managed care as a strong sector and called CVS one of the biggest winners as Walgreens fades, reinforcing the market’s view that CVS may benefit from industry consolidation. Cramer’s Stop Trading: CVS Health
• Positive Sentiment: CVS CEO comments that Aetna has medical costs “under control” ahead of second-quarter earnings suggest margin pressure may be manageable, which could support investor confidence going into results. CVS CEO says Aetna has a handle on medical costs in advance of Q2 earnings
• Positive Sentiment: Heavy call-option buying and multiple articles flagging CVS as a momentum/trending stock point to increased trader interest and possible speculation on further upside. Here’s Why CVS Health (CVS) is a Strong Momentum Stock
• Neutral Sentiment: CVS also continued to get publicity around its Specialty Pharmacy and HIV-treatment support programs, which helps the company’s long-term image but is unlikely to move the stock immediately. HIV Is Now a Manageable Chronic Condition – How CVS Specialty Helps Patients Start and Stay on Treatment
• Negative Sentiment: A major risk factor is the reported $440 million Justice Department settlement involving CVS and Omnicare, which could weigh on sentiment by reminding investors of legal and regulatory overhangs. CVS, Omnicare reach $440M Justice Department settlement
• Negative Sentiment: A market-wrap note showing CVS trading lower on the day indicates investors are still taking profits or staying cautious ahead of earnings and settlement-related headlines. CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. 0.85% of the stock is currently owned by insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.